OREXIGEN Therapeutics Initiates Fourth Phase III Trial For Contrave(TM) To Treat Obesity

Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders including obesity, today announced the initiation of the fourth trial in its Phase III clinical trial program for its lead product candidate Contrave? as a treatment for obesity. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 15th, 2007